BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12438542)

  • 1. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization.
    Steinberg R; Alonso R; Rouquier L; Desvignes C; Michaud JC; Cudennec A; Jung M; Simiand J; Griebel G; Emonds-Alt X; Le Fur G; Soubrié P
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1180-8. PubMed ID: 12438542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
    Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential activation of the epithelial and smooth muscle NK1 receptors by synthetic tachykinin agonists in guinea-pig trachea.
    Figini M; Emanueli C; Bertrand C; Sicuteri R; Regoli D; Geppetti P
    Br J Pharmacol; 1997 Jun; 121(4):773-81. PubMed ID: 9208147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tachykinin regulation of cholinergic transmission in the limbic/prefrontal territory of the rat dorsal striatum: implication of new neurokinine 1-sensitive receptor binding site and interaction with enkephalin/mu opioid receptor transmission.
    Pérez S; Tierney A; Deniau JM; Kemel ML
    J Neurochem; 2007 Dec; 103(6):2153-63. PubMed ID: 17949415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ava[L-Pro9,N-MeLeu10] substance P(7-11) (GR 73632) and Sar9, Met(O2)11 increase distention-induced peristalsis through activation of neurokinin-1 receptors on smooth muscle and interstitial cells of cajal.
    Nieuwmeyer F; Ye J; Huizinga JD
    J Pharmacol Exp Ther; 2006 Apr; 317(1):439-45. PubMed ID: 16330493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
    Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
    Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor.
    McLean S; Ganong A; Seymour PA; Bryce DK; Crawford RT; Morrone J; Reynolds LS; Schmidt AW; Zorn S; Watson J; Fossa A; DePasquale M; Rosen T; Nagahisa A; Tsuchiya M; Heym J
    J Pharmacol Exp Ther; 1996 May; 277(2):900-8. PubMed ID: 8627572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
    Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
    Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function.
    Steinberg R; Alonso R; Griebel G; Bert L; Jung M; Oury-Donat F; Poncelet M; Gueudet C; Desvignes C; Le Fur G; Soubrié P
    J Pharmacol Exp Ther; 2001 Nov; 299(2):449-58. PubMed ID: 11602654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of the central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat.
    Field MJ; McCleary S; Boden P; Suman-Chauhan N; Hughes J; Singh L
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1226-32. PubMed ID: 9618426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
    Kudlacz EM; Shatzer SA; Knippenberg RW; Logan DE; Poirot M; van Giersbergen PL; Burkholder TP
    J Pharmacol Exp Ther; 1996 May; 277(2):840-51. PubMed ID: 8627566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists.
    Duffy RA; Varty GB; Morgan CA; Lachowicz JE
    J Pharmacol Exp Ther; 2002 May; 301(2):536-42. PubMed ID: 11961054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
    Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor.
    McLean S; Ganong A; Seymour PA; Snider RM; Desai MC; Rosen T; Bryce DK; Longo KP; Reynolds LS; Robinson G
    J Pharmacol Exp Ther; 1993 Oct; 267(1):472-9. PubMed ID: 7693914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
    Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
    Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization and function of NK(3) subtype tachykinin receptors of layer V pyramidal neurons of the guinea-pig medial prefrontal cortex.
    Simmons MA; Sobotka-Briner CD; Medd AM
    Neuroscience; 2008 Oct; 156(4):987-94. PubMed ID: 18801417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist.
    Emonds-Alt X; Doutremepuich JD; Heaulme M; Neliat G; Santucci V; Steinberg R; Vilain P; Bichon D; Ducoux JP; Proietto V
    Eur J Pharmacol; 1993 Dec; 250(3):403-13. PubMed ID: 7509286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurokinin receptor modulation of respiratory activity in the rabbit.
    Bongianni F; Mutolo D; Cinelli E; Pantaleo T
    Eur J Neurosci; 2008 Jun; 27(12):3233-43. PubMed ID: 18554294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The new neurokinin 1-sensitive receptor mediates the facilitation by endogenous tachykinins of the NMDA-evoked release of acetylcholine after suppression of dopaminergic transmission in the matrix of the rat striatum.
    Kemel ML; Pérez S; Beaujouan JC; Jabourian M; Soubrié P; Glowinski J
    J Neurochem; 2003 Oct; 87(2):487-96. PubMed ID: 14511126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.